Open Label Phase I Trial in Healthy Chinese Male and Female Volunteers to Investigate Pharmacokinetics and Pharmacodynamics of Idarucizumab to Reverse Dabigatran Anticoagulant Activity

Trial Profile

Open Label Phase I Trial in Healthy Chinese Male and Female Volunteers to Investigate Pharmacokinetics and Pharmacodynamics of Idarucizumab to Reverse Dabigatran Anticoagulant Activity

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Idarucizumab (Primary) ; Dabigatran etexilate
  • Indications Blood coagulation disorders
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 20 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 12 Sep 2017 Planned End Date changed from 1 Sep 2017 to 14 Sep 2017.
    • 12 Sep 2017 Planned primary completion date changed from 20 Aug 2017 to 14 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top